Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Diacerein is a synthetic anthraquinone derivative primarily utilized as a disease-modifying osteoarthritis drug (DMOAD). With the Chemical Abstracts Service (CAS) registry number 97861-40-6, its molecular formula is C21H18O8. This compound functions not merely as a symptomatic relief agent but as a therapeutic intervention targeting the underlying pathophysiology of joint degeneration. Unlike traditional non-steroidal anti-inflammatory drugs (NSAIDs) that only mask pain and inflammation, Diacerein exerts a dual mechanism of action. First, it inhibits interleukin-1 beta (IL-1β), a key pro-inflammatory cytokine responsible for cartilage destruction and synovial inflammation. By suppressing IL-1β production, it reduces the inflammatory cascade within the joint space. Second, Diacerein stimulates the synthesis of proteoglycans by chondrocytes, thereby promoting cartilage repair and slowing down the progressive loss of articular tissue.
Clinically, Diacerein is widely prescribed for the management of osteoarthritis, particularly affecting weight-bearing joints such as the knees and hips, as well as the hands. It is often indicated for patients who require long-term symptom control while attempting to preserve joint structure. The drug is typically administered orally in capsule form, with a delayed onset of action compared to analgesics; significant clinical benefits usually manifest after several weeks of continuous therapy. While generally well-tolerated, common adverse effects include gastrointestinal disturbances, most notably diarrhea, which is often transient. Despite its efficacy in reducing pain and improving functional mobility, regulatory approval varies globally, with availability being prominent in Europe and parts of Asia, though it remains unapproved by the FDA in the United States. Ongoing research continues to evaluate its potential role in delaying joint replacement surgery and enhancing quality of life for individuals suffering from chronic degenerative joint diseases. Its unique profile distinguishes it as a specialized agent aimed at modifying disease progression rather than solely alleviating acute symptoms.